CA3078724A1 - Oral testosterone tridecanoate therapy - Google Patents

Oral testosterone tridecanoate therapy Download PDF

Info

Publication number
CA3078724A1
CA3078724A1 CA3078724A CA3078724A CA3078724A1 CA 3078724 A1 CA3078724 A1 CA 3078724A1 CA 3078724 A CA3078724 A CA 3078724A CA 3078724 A CA3078724 A CA 3078724A CA 3078724 A1 CA3078724 A1 CA 3078724A1
Authority
CA
Canada
Prior art keywords
fixed dose
testosterone
dosing regimen
provides
method comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3078724A
Other languages
English (en)
French (fr)
Inventor
Nachiappan Chidambaram
Satish Kumar Nachaegari
Mahesh V. Patel
Kilyoung Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lipocine Inc
Original Assignee
Lipocine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipocine Inc filed Critical Lipocine Inc
Publication of CA3078724A1 publication Critical patent/CA3078724A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3078724A 2016-11-30 2017-11-30 Oral testosterone tridecanoate therapy Pending CA3078724A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662428167P 2016-11-30 2016-11-30
US201662428317P 2016-11-30 2016-11-30
US62/428,167 2016-11-30
US62/428,317 2016-11-30
PCT/US2017/064083 WO2018102618A1 (en) 2016-11-30 2017-11-30 Oral testosterone tridecanoate therapy

Publications (1)

Publication Number Publication Date
CA3078724A1 true CA3078724A1 (en) 2018-06-07

Family

ID=62240656

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3078724A Pending CA3078724A1 (en) 2016-11-30 2017-11-30 Oral testosterone tridecanoate therapy

Country Status (6)

Country Link
US (6) US20180153905A1 (https=)
EP (1) EP3548037B1 (https=)
JP (1) JP2020500864A (https=)
CA (1) CA3078724A1 (https=)
ES (1) ES2983643T3 (https=)
WO (1) WO2018102618A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2604943C (en) 2005-04-15 2013-09-17 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
CA3078724A1 (en) 2016-11-30 2018-06-07 Nachiappan Chidambaram Oral testosterone tridecanoate therapy
WO2020018974A1 (en) * 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
US11931367B2 (en) 2021-09-30 2024-03-19 Lipocine Inc. Oral (17-ß)-3-oxoandrost-4-en-17-yl tridecanoate therapy
US11564933B2 (en) 2019-04-12 2023-01-31 Tolmar, Inc. Methods of treating testosterone deficiency
US12257257B2 (en) * 2023-07-27 2025-03-25 Lipocine, Inc. Testosterone dodecanoate compositions and methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130225544A1 (en) * 2009-01-08 2013-08-29 Lipocine Inc. Lipobalanced long chain testosterone esters for oral delivery
US20140288039A1 (en) 2009-01-08 2014-09-25 Lipocine Inc. Lipobalanced long chain testosterone prodrugs for oral delivery
TW201521731A (zh) 2013-03-15 2015-06-16 利波辛股份有限公司 用於口服之脂平衡的長鏈睪固酮酯
US10245273B2 (en) 2013-12-26 2019-04-02 Clarus Therapeutics, Inc. Oral pharmaceutical products and methods of use combining testosterone esters with hypolipidemic agents
AU2015308614B2 (en) 2014-08-28 2021-02-18 Lipocine Inc. Pharmaceutical composition and methods
CA3078724A1 (en) * 2016-11-30 2018-06-07 Nachiappan Chidambaram Oral testosterone tridecanoate therapy

Also Published As

Publication number Publication date
US12303517B1 (en) 2025-05-20
EP3548037B1 (en) 2024-07-03
WO2018102618A1 (en) 2018-06-07
EP3548037A1 (en) 2019-10-09
US10881670B2 (en) 2021-01-05
US12161651B1 (en) 2024-12-10
US20200222426A1 (en) 2020-07-16
US20180153905A1 (en) 2018-06-07
US11992496B1 (en) 2024-05-28
US11672807B1 (en) 2023-06-13
ES2983643T3 (es) 2024-10-24
JP2020500864A (ja) 2020-01-16
EP3548037A4 (en) 2020-07-29

Similar Documents

Publication Publication Date Title
US11559530B2 (en) Oral testosterone undecanoate therapy
US12303517B1 (en) Oral testosterone therapy
Raju et al. Berberine loaded nanostructured lipid carrier for Alzheimer's disease: design, statistical optimization and enhanced in vivo performance
EP2861072B1 (en) Natural combination hormone replacement formulations and therapies
US11464735B2 (en) Fixed dose oral testosterone undecanoate compositions and use thereof
US11433083B2 (en) High-strength testosterone undecanoate compositions
EP3600285A1 (en) Topical compositions and methods of treatment
CN111432805B (zh) 3α-乙炔基-3β-羟基雄甾烷-17-酮肟的药物制剂
CN114344309A (zh) 一种别孕烷醇酮衍生物自乳化制剂及其制备方法
AU2019200097A1 (en) Lipobalanced long chain testosterone esters for oral delivery
AU2010218424B2 (en) Narcotic emulsion formulations for treatment of cancer pain
JP2016514706A5 (https=)
RU2779262C2 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ 3α-ЭТИНИЛ-3β-ГИДРОКСИАНДРОСТАН-17-ОНА ОКСИМА
CA3050250A1 (en) Opioid agonist / antagonist combination dosage forms

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20221129

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240910

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241022

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241122

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241122

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241122

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251121

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251121

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251211

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260408